COMPOSITION POUR ATTÉNUER, PRÉVENIR OU TRAITER UN TROUBLE DU SOMMEIL OU COMPOSITION POUR SUPPRIMER LA RÉSISTANCE À UN AGONISTE DU SITE DE LIAISON AUX BENZODIAZÉPINES DU RÉCEPTEUR GABA-A, OU POUR ATTÉNUER UN EFFET SECONDAIRE D'UN AGONISTE DU SITE DE LIAISON AUX BENZODIAZÉPINES DU RÉCEPTEUR GABA-A, CHAQUE COMPOSITION COMPRENANT DU PHLOROGLUCINOL EN TANT QUE PRINCIPE ACTIF
CHO, Sueng Mok,조승목,UM, Min Young,엄민영,YOON, Min Seok,윤민석,YANG, Hye Jin,양혜진,LEE, Jae Kwang,이재광,JUNG, Jong Hoon,정종훈
申请号：
KRKR2018/005389
公开号：
WO2018/208107A1
申请日:
2018.05.10
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
A pharmaceutical composition for preventing or treating somnipathy or a health function food composition for alleviating somnipathy, each composition comprising phloroglucinol as an effective ingredient, according to the present invention can quickly and reliably induce or maintain sleep. Meanwhile, the composition can prevent a repeated awakening phenomenon without changing a physiological sleep architecture, has no residual sedation, which may particularly give rise to incomplete daytime activities or recognition ability, does not induce resistance after long-term administration, and does not generate a side-effect of conventional benzodiazepine binding side agonist of the GABA-A receptor. In addition, a pharmaceutical composition or a health functional food composition comprising phloroglucinol as an effective ingredient for suppressing resistance to a benzodiazepine binding site agonist of the GABA-A receptor or alleviating a side effect of a benzodiazepine binding site agonist of the GABA-A receptor, according to the present invention can alleviate a side effect of a benzodiazepine binding side agonist of the GABA-A receptor or suppress resistance that occurs with the long-term administration of a benzodiazepine binding site agonist of the GABA-A receptor. Further, a pharmaceutical composition comprising phloroglucinol and a benzodiazepine binding site agonist of the GABA-A receptor as effective ingredients for preventing or treating somnipathy according to the present invention has a reduced content of the benzodiazepine binding site agonist of the GABA-A receptor, which may increase the quantity of sleep, but degrade the quality of sleep, acting as a cause of various side effects, whereby the side effects of the benzodiazepine binding site agonist of the GABA-A receptor can be reduced or the resistance occurring with the long-term administration of the benzodiazepine binding site agonist of the GABA-A receptor can be suppressed.La présente invention concerne
